Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 23 | 2025 | 146 | 5.480 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 4 | 2025 | 54 | 2.420 |
Why?
|
| Electrocardiography | 4 | 2024 | 976 | 2.070 |
Why?
|
| Seizures, Febrile | 4 | 2025 | 24 | 1.960 |
Why?
|
| Epilepsy | 7 | 2024 | 874 | 1.850 |
Why?
|
| Drug Resistant Epilepsy | 12 | 2025 | 205 | 1.730 |
Why?
|
| Critical Care | 3 | 2024 | 656 | 1.300 |
Why?
|
| Electroencephalography | 8 | 2023 | 869 | 1.250 |
Why?
|
| Dexamethasone | 3 | 2025 | 271 | 1.250 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 3 | 2017 | 24 | 1.160 |
Why?
|
| Anticonvulsants | 10 | 2025 | 384 | 1.050 |
Why?
|
| Brain Injuries | 9 | 2023 | 705 | 1.030 |
Why?
|
| Benzodiazepines | 7 | 2025 | 102 | 1.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2017 | 63 | 0.880 |
Why?
|
| Epileptic Syndromes | 2 | 2021 | 29 | 0.860 |
Why?
|
| Neurophysiological Monitoring | 1 | 2023 | 37 | 0.830 |
Why?
|
| Brain Diseases | 2 | 2023 | 300 | 0.820 |
Why?
|
| Child | 34 | 2025 | 24620 | 0.800 |
Why?
|
| Nervous System Diseases | 2 | 2024 | 373 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 509 | 0.700 |
Why?
|
| Heart Arrest | 2 | 2024 | 357 | 0.700 |
Why?
|
| Cytokines | 2 | 2025 | 1292 | 0.700 |
Why?
|
| Neurology | 1 | 2022 | 107 | 0.690 |
Why?
|
| White Matter | 1 | 2022 | 185 | 0.680 |
Why?
|
| Immunotherapy | 1 | 2025 | 678 | 0.660 |
Why?
|
| Time-to-Treatment | 4 | 2025 | 186 | 0.650 |
Why?
|
| Child, Preschool | 24 | 2025 | 14155 | 0.620 |
Why?
|
| Mitochondria | 3 | 2017 | 680 | 0.620 |
Why?
|
| Blood Pressure | 1 | 2024 | 1351 | 0.610 |
Why?
|
| Hippocampus | 5 | 2022 | 824 | 0.570 |
Why?
|
| Encephalitis | 3 | 2024 | 109 | 0.560 |
Why?
|
| Mitochondrial Diseases | 2 | 2007 | 132 | 0.470 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2005 | 70 | 0.470 |
Why?
|
| Hospitals, Pediatric | 5 | 2022 | 768 | 0.450 |
Why?
|
| Infant | 19 | 2025 | 12611 | 0.450 |
Why?
|
| Neurons | 4 | 2017 | 1933 | 0.440 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 457 | 0.440 |
Why?
|
| Retrospective Studies | 16 | 2025 | 16350 | 0.430 |
Why?
|
| Humans | 42 | 2025 | 125138 | 0.430 |
Why?
|
| Heart Rate | 1 | 2016 | 582 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2018 | 1243 | 0.410 |
Why?
|
| Kainic Acid | 4 | 2020 | 24 | 0.370 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2022 | 88 | 0.360 |
Why?
|
| Injections, Spinal | 3 | 2025 | 126 | 0.350 |
Why?
|
| Male | 30 | 2025 | 61465 | 0.340 |
Why?
|
| Rats | 9 | 2022 | 3728 | 0.330 |
Why?
|
| Seawater | 1 | 2019 | 12 | 0.330 |
Why?
|
| Bivalvia | 1 | 2019 | 14 | 0.330 |
Why?
|
| Symbiosis | 1 | 2019 | 62 | 0.320 |
Why?
|
| Blotting, Western | 5 | 2017 | 1111 | 0.300 |
Why?
|
| Seizures | 6 | 2023 | 869 | 0.300 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2007 | 3 | 0.290 |
Why?
|
| Adolescent | 15 | 2025 | 19424 | 0.290 |
Why?
|
| Disease Progression | 2 | 2024 | 2084 | 0.280 |
Why?
|
| Glutathione | 2 | 2007 | 196 | 0.270 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 228 | 0.260 |
Why?
|
| Chaperonin 60 | 1 | 2006 | 29 | 0.250 |
Why?
|
| Bacteria | 1 | 2019 | 477 | 0.250 |
Why?
|
| Peroxynitrous Acid | 1 | 2005 | 7 | 0.250 |
Why?
|
| Gene Products, tat | 1 | 2005 | 27 | 0.240 |
Why?
|
| Stress, Physiological | 2 | 2006 | 256 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1265 | 0.230 |
Why?
|
| Respiration Disorders | 1 | 2024 | 32 | 0.230 |
Why?
|
| Pediatrics | 2 | 2024 | 1158 | 0.230 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 290 | 0.220 |
Why?
|
| Autophagy | 1 | 2007 | 395 | 0.220 |
Why?
|
| Glutamic Acid | 1 | 2005 | 204 | 0.220 |
Why?
|
| Heart | 2 | 2021 | 731 | 0.220 |
Why?
|
| Clinical Protocols | 1 | 2025 | 240 | 0.220 |
Why?
|
| Hospitalization | 3 | 2022 | 1785 | 0.210 |
Why?
|
| Female | 23 | 2025 | 66719 | 0.210 |
Why?
|
| Animals | 14 | 2022 | 34304 | 0.200 |
Why?
|
| Time Factors | 4 | 2024 | 6302 | 0.200 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 377 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2025 | 6124 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 292 | 0.200 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2024 | 479 | 0.200 |
Why?
|
| Diet, Ketogenic | 2 | 2021 | 22 | 0.190 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 532 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1158 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2024 | 320 | 0.180 |
Why?
|
| Infectious Encephalitis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 274 | 0.180 |
Why?
|
| Professional Practice Gaps | 1 | 2020 | 15 | 0.170 |
Why?
|
| Brain | 4 | 2007 | 3015 | 0.170 |
Why?
|
| Photoperiod | 1 | 2019 | 20 | 0.160 |
Why?
|
| Critical Illness | 1 | 2024 | 599 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2021 | 4824 | 0.160 |
Why?
|
| Synapses | 2 | 2022 | 452 | 0.150 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2017 | 42 | 0.150 |
Why?
|
| Receptors, AMPA | 1 | 2018 | 48 | 0.150 |
Why?
|
| Inflammation | 1 | 2025 | 1447 | 0.140 |
Why?
|
| Post-Synaptic Density | 1 | 2017 | 11 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 370 | 0.140 |
Why?
|
| Emergency Treatment | 1 | 2018 | 84 | 0.140 |
Why?
|
| Synaptotagmin I | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2017 | 9 | 0.140 |
Why?
|
| Poly ADP Ribosylation | 1 | 2017 | 1 | 0.140 |
Why?
|
| Dendritic Spines | 1 | 2017 | 60 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1684 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4407 | 0.130 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2016 | 19 | 0.130 |
Why?
|
| Connexin 43 | 1 | 2016 | 29 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2017 | 360 | 0.130 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2016 | 60 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 825 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 398 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 145 | 0.120 |
Why?
|
| Antioxidants | 2 | 2009 | 355 | 0.120 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2016 | 171 | 0.120 |
Why?
|
| Glasgow Coma Scale | 2 | 2006 | 194 | 0.110 |
Why?
|
| Cerebral Cortex | 3 | 2006 | 454 | 0.110 |
Why?
|
| Microscopy, Electron | 2 | 2017 | 396 | 0.100 |
Why?
|
| Young Adult | 6 | 2025 | 9060 | 0.100 |
Why?
|
| Child Abuse | 2 | 2005 | 197 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3606 | 0.090 |
Why?
|
| Myocardium | 1 | 2016 | 1022 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2024 | 433 | 0.090 |
Why?
|
| Hydrogenase | 1 | 2019 | 1 | 0.080 |
Why?
|
| Mytilidae | 1 | 2019 | 1 | 0.080 |
Why?
|
| Hydrothermal Vents | 1 | 2019 | 1 | 0.080 |
Why?
|
| Biodiversity | 1 | 2019 | 64 | 0.080 |
Why?
|
| Ecosystem | 1 | 2019 | 77 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 127 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2023 | 3310 | 0.080 |
Why?
|
| Cytochromes c | 2 | 2005 | 51 | 0.070 |
Why?
|
| Metagenome | 1 | 2019 | 148 | 0.070 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 96 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2815 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1704 | 0.070 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 362 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2009 | 818 | 0.070 |
Why?
|
| Cell Respiration | 1 | 2007 | 23 | 0.070 |
Why?
|
| Electron Transport | 1 | 2007 | 55 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 45 | 0.070 |
Why?
|
| Cell Death | 2 | 2005 | 239 | 0.070 |
Why?
|
| Whole-Body Irradiation | 1 | 2007 | 60 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2527 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2009 | 169 | 0.070 |
Why?
|
| Nitrogen | 1 | 2007 | 145 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2006 | 874 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 247 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3044 | 0.060 |
Why?
|
| Lactate Dehydrogenases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2021 | 1027 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 15 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 94 | 0.060 |
Why?
|
| Base Sequence | 1 | 2019 | 3109 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 98 | 0.060 |
Why?
|
| Sex Factors | 3 | 2020 | 1275 | 0.060 |
Why?
|
| Animals, Newborn | 2 | 2005 | 1018 | 0.060 |
Why?
|
| Microbiota | 1 | 2019 | 387 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 37 | 0.060 |
Why?
|
| Hashimoto Disease | 1 | 2024 | 21 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 121 | 0.060 |
Why?
|
| Accidents | 1 | 2004 | 15 | 0.060 |
Why?
|
| Asphyxia | 1 | 2004 | 14 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 4597 | 0.060 |
Why?
|
| Glasgow Outcome Scale | 1 | 2004 | 46 | 0.050 |
Why?
|
| Florida | 1 | 2024 | 78 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 898 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 108 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 21 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 152 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1762 | 0.050 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 30 | 0.050 |
Why?
|
| Transcriptome | 1 | 2019 | 978 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 802 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 75 | 0.050 |
Why?
|
| Phenotype | 2 | 2023 | 4271 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 168 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 115 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 196 | 0.050 |
Why?
|
| Midazolam | 1 | 2021 | 45 | 0.050 |
Why?
|
| Apoptosis | 2 | 2005 | 1819 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2003 | 139 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8275 | 0.050 |
Why?
|
| Cannabidiol | 1 | 2021 | 22 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2006 | 765 | 0.040 |
Why?
|
| Epilepsy, Generalized | 1 | 2021 | 64 | 0.040 |
Why?
|
| Phenobarbital | 1 | 2020 | 36 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1119 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2021 | 47 | 0.040 |
Why?
|
| Phenytoin | 1 | 2020 | 63 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2182 | 0.040 |
Why?
|
| Biomarkers | 2 | 2006 | 3105 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 1130 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12276 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 80 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 552 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 298 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 130 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1035 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 17739 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 433 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2017 | 76 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1425 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1362 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 728 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 627 | 0.030 |
Why?
|
| Prognosis | 1 | 2006 | 4685 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1172 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 380 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2019 | 493 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 715 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 692 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 1307 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 700 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 2004 | 156 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1187 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2020 | 1054 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 19666 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3756 | 0.020 |
Why?
|
| Middle Aged | 2 | 2025 | 26688 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 29470 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2005 | 43 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 133 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 147 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 163 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 335 | 0.010 |
Why?
|
| Y Chromosome | 1 | 2004 | 47 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 262 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2006 | 244 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 156 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 207 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2006 | 229 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 273 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 281 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2003 | 2 | 0.010 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2003 | 5 | 0.010 |
Why?
|
| X Chromosome | 1 | 2004 | 338 | 0.010 |
Why?
|
| United States | 1 | 2018 | 10884 | 0.010 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2004 | 81 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2004 | 257 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 461 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 506 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 820 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 404 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1294 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 1181 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1621 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1910 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 2061 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 2603 | 0.010 |
Why?
|